Corteva Business Summary

Corteva, Inc. (CTVA) operates as a global pure-play agricultural technology leader, generating revenue through the development and sale of advanced seed genetics and crop protection solutions, supplemented by technology licensing and digital agronomy services. The company’s business is divided into two primary segments: Seed, which focuses on enhancing yield and weather resistance through proprietary germplasm and traits (e.g., Pioneer brand), and Crop Protection, which provides a diverse portfolio of herbicides, fungicides, and biologicals. As of February 2026, Corteva is executing a strategic separation into two independent, publicly traded entities—"New Corteva" (Crop Protection) and "SpinCo" (Seed)—targeted for completion in the second half of 2026 to optimize capital allocation and operational focus. Within the global market, Corteva maintains a dominant position alongside primary competitors Bayer Crop Science, Syngenta Group, and BASF Agricultural Solutions, distinguishing itself through a high-margin innovation pipeline and a recent $610 million litigation resolution with Bayer that accelerates its corn trait out-licensing capabilities. Originally formed in 2019 as a spin-off from the DowDuPont merger, the company is currently led by Chief Executive Officer Charles "Chuck" Magro, the former CEO of Nutrien and Agrium, who brings extensive experience in large-scale agricultural integration. The executive team includes David Johnson as EVP and Chief Financial Officer, and Samuel Eathington as EVP and Chief Technology and Digital Officer, who oversees the firm’s R&D and digital platforms. Key business unit leadership includes Judd O’Connor, EVP of the Seed Business Unit, and Robert King, EVP of the Crop Protection Business Unit. The Board of Directors is chaired by Gregory Page, the retired Chairman and CEO of Cargill, and includes notable industry veterans such as Lamberto Andreotti (formerly of Bristol-Myers Squibb) and Klaus Engel (formerly of Evonik). Major institutional backing is provided by investors such as BlackRock and Vanguard, supporting the company's transition toward royalty neutrality and expanded biological offerings.